Aqua Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Acticlate (doxycyline hyclate), a tetracycline antibacterial for the treatment of susceptible infections including adjunctive therapy in severe acne.
Acticlate is a new formulation of oral doxycycline. The 150mg strength has been designed with two functional scores and is substantially reduced in tablet size compared to other available scored doxycycline tablets.
Acticlate will be available in 75mg and 150mg (dual-scored) strength tablets.
For more information call (610) 644-7000 or visit Aquapharm.com.